Compare FTAI Aviation Ltd (FTAI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Repligen Corporation Common Stock — how do they compare? FTAI Aviation Ltd trades at $162 (market cap $17.14B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 1.2% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 24 Days and Repligen Corporation Common Stock for 0 Days on average.
| FTAI | RGEN | |
|---|---|---|
Market Cap | $17.14B | $11.14B |
Volume | 3,282,791 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $310.04 | $194.57 |
52-Week Low | $152.80 | $102.87 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $20.25B | $11.02B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $166.87, up 0.81% today, but technical indicators signal a bearish trend with key support at $163 and resistance at $169. The company reported strong 2025 revenue of $2.51 billion and net income of $501 million, though recent quarters have missed EPS expectations. Recent developments include a $500 million share buyback program and a strategic acquisition of 27 Boeing 737-700 aircraft, highlighting growth initiatives in aerospace services.
The outlook is mixed: analyst consensus is unanimously bullish with a $321.25 price target, but risks include volatile cash flows and competitive pressures. Upside potential hinges on execution of the buyback and aerospace segment growth, while earnings misses and negative operating cash flow pose near-term challenges for investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
